REDWOOD CITY, Calif.–(BUSINESS WIRE) – June 7, 2018 — Atreca, Inc., a
biotechnology company focused on developing novel therapeutics based on a deep
understanding of the human immune response, announced today that Norman Michael
Greenberg, Ph.D., Senior Vice President and Chief Scientific Officer at Atreca, will
deliver a presentation highlighting progress of the Company’s advancing immuno-
oncology pipeline during the 2018 World Preclinical Congress (WPC) Annual Meeting,
which is taking place at Westin Copley Place in Boston, MA, June 18-21, 2018. Dr.
Greenberg will report on results of Atreca’s R&D engine, Immune Repertoire Capture®
(IRC™), to identify therapeutic antibodies for development based on patients’
responses to cancer immunotherapy.
“The power of our IRC™ technology lies in its ability to accurately discover anti-ˇtumor
antibodies in patients who have achieved successful outcomes following anti-cancer
treatments, such as checkpoint inhibitor immunotherapy,” said John A. Orwin, Atreca’s
President and Chief Executive Officer. “As highlighted in this promising research, our
recombinantly expressed antibodies were able to cause tumor regression and induce
durable immunity in in vivo preclinical cancer models. We are delighted to report on the
progress of this and other key research at Atreca as we continue to advance our
pipeline toward entry into the clinic next year.”
Details regarding the oral presentation are available on the WPC website and are also
Presentation Title: Discovery and Characterization of Functional Anti-ˇTumor Antibodies from Non-ˇProgressing Cancer Patients Undergoing Immunotherapy
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics drawn
from human immune responses, including effective anti-ˇcancer immune responses. We
are able to measure and analyze the structure of clinically relevant immune responses
to identify the antibodies, T cell receptors (TCRs), and targets that are key to successful
treatment outcomes. Atreca’s proprietary Immune Repertoire Capture® (IRC™)
technology profiles a patient’s immune response at the single-ˇcell level at very high
throughput essentially without bias or error. This approach enables the identification,
generation, and analysis of functional human antibody and TCR sequences from single
B and T cells without prior knowledge of antigen. Atreca is advancing a pipeline of
candidates designed to engage the human immune response in oncology and other
indications, thus driving better therapeutic outcomes. For more information on Atreca,
please visit www.atreca.com.
EVP and Chief Financial Officer
Justin Jackson, 212-ˇ213-ˇ0006, ext. 327
John Grimaldi, 212-ˇ213-ˇ0006, ext. 362
Source: Atreca, Inc.